# A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

> **NCT07217067** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 165 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** PKN605
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07217067
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-28
- **Primary completion:** 2027-09-09
- **Final completion:** 2027-09-09
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217067, "A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07217067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*